Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jul 1;100(1):107–114. doi: 10.1172/JCI119501

Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice.

K Tsukamoto 1, P Smith 1, J M Glick 1, D J Rader 1
PMCID: PMC508170  PMID: 9202062

Abstract

Apolipoprotein E (apoE) plays a key role in lipoprotein metabolism and may have other important biological functions. In humans, there are three common, naturally occurring isoforms of apoE that are associated with differences in lipid levels and atherosclerosis. However, the direct in vivo effects of the apoE isoforms on lipoprotein metabolism and atherosclerosis are not yet fully understood. To investigate the effect of the apoE isoforms in vivo, we constructed second-generation recombinant adenoviruses encoding each of the apoE isoforms. These recombinant adenoviruses were injected intravenously into apoE-deficient mice fed a Western diet (mean baseline cholesterol level 1401 mg/dl) in order to study their effects in the absence of endogenous mouse apoE. Hepatic expression of apoE3 and apoE4 completely normalized the lipoprotein profile; 3 d after injection, mean plasma cholesterol levels were 194 and 217 mg/ dl, respectively, and this effect was maintained for at least 6 wk. Expression of apoE2 had much less effect on lipoprotein levels (mean cholesterol level 752 mg/dl 3 d after injection), despite much higher plasma levels of apoE2 compared with apoE3 and apoE4; by 6 wk after injection the cholesterol levels had returned to baseline levels in the apoE2-expressing mice. Expression of all three isoforms significantly increased HDL cholesterol levels by approximately threefold and was independent of the cholesterol-lowering effect. ApoE transgene expression was substantially prolonged compared with that achieved using a first generation adenovirus and apoE was readily detected in plasma 3 mo after virus injection. These studies demonstrate: (a) prolonged in vivo expression of human apoE isoforms in apoE deficient mice after second-generation recombinant adenovirus-mediated somatic gene transfer; and (b) significantly impaired ability of apoE2 in vivo to mediate clearance of remnant lipoproteins in apoE-deficient mice fed a Western diet compared with apoE3 and apoE4.

Full Text

The Full Text of this article is available as a PDF (259.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beisiegel U. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. Curr Opin Lipidol. 1995 Jun;6(3):117–122. doi: 10.1097/00041433-199506000-00002. [DOI] [PubMed] [Google Scholar]
  2. Brewer H. B., Jr, Zech L. A., Gregg R. E., Schwartz D., Schaefer E. J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 1983 May;98(5 Pt 1):623–640. doi: 10.7326/0003-4819-98-5-623. [DOI] [PubMed] [Google Scholar]
  3. Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1–21. doi: 10.1161/01.atv.8.1.1. [DOI] [PubMed] [Google Scholar]
  4. Ehnholm C., Mahley R. W., Chappell D. A., Weisgraber K. H., Ludwig E., Witztum J. L. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A. 1984 Sep;81(17):5566–5570. doi: 10.1073/pnas.81.17.5566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196–6200. doi: 10.1073/pnas.91.13.6196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feussner G., Dobmeyer J., Gröne H. J., Lohmer S., Wohlfeil S. A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia. Am J Hum Genet. 1996 Feb;58(2):281–291. [PMC free article] [PubMed] [Google Scholar]
  7. Gerdes L. U., Gerdes C., Klausen I. C., Faergeman O. Generation of analytic plasma lipoprotein profiles using two prepacked superose 6B columns. Clin Chim Acta. 1992 Jan 31;205(1-2):1–9. doi: 10.1016/0009-8981(92)90348-t. [DOI] [PubMed] [Google Scholar]
  8. Ghiselli G., Schaefer E. J., Gascon P., Breser H. B., Jr Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science. 1981 Dec 11;214(4526):1239–1241. doi: 10.1126/science.6795720. [DOI] [PubMed] [Google Scholar]
  9. Gregg R. E., Zech L. A., Schaefer E. J., Brewer H. B., Jr Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 1981 Feb 6;211(4482):584–586. doi: 10.1126/science.7455696. [DOI] [PubMed] [Google Scholar]
  10. Gregg R. E., Zech L. A., Schaefer E. J., Stark D., Wilson D., Brewer H. B., Jr Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986 Sep;78(3):815–821. doi: 10.1172/JCI112645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Havel R. J. The formation of LDL: mechanisms and regulation. J Lipid Res. 1984 Dec 15;25(13):1570–1576. [PubMed] [Google Scholar]
  12. Herz J., Gerard R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2812–2816. doi: 10.1073/pnas.90.7.2812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Imler J. L. Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995 Sep;13(13):1143–1151. doi: 10.1016/0264-410x(95)00032-v. [DOI] [PubMed] [Google Scholar]
  14. Kashyap V. S., Santamarina-Fojo S., Brown D. R., Parrott C. L., Applebaum-Bowden D., Meyn S., Talley G., Paigen B., Maeda N., Brewer H. B., Jr Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest. 1995 Sep;96(3):1612–1620. doi: 10.1172/JCI118200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kozarsky K. F., Jooss K., Donahee M., Strauss J. F., 3rd, Wilson J. M. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet. 1996 May;13(1):54–62. doi: 10.1038/ng0596-54. [DOI] [PubMed] [Google Scholar]
  16. Kozarsky K. F., Wilson J. M. Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993 Jun;3(3):499–503. doi: 10.1016/0959-437x(93)90126-a. [DOI] [PubMed] [Google Scholar]
  17. Kurosaka D., Teramoto T., Matsushima T., Yokoyama T., Yamada A., Aikawa T., Miyamoto Y., Kurokawa K. Apolipoprotein E deficiency with a depressed mRNA of normal size. Atherosclerosis. 1991 May;88(1):15–20. doi: 10.1016/0021-9150(91)90252-x. [DOI] [PubMed] [Google Scholar]
  18. Leiden J. M. Adenovirus-mediated gene transfer as an in vivo probe of lipoprotein metabolism. Circulation. 1996 Nov 1;94(9):2046–2051. doi: 10.1161/01.cir.94.9.2046. [DOI] [PubMed] [Google Scholar]
  19. Linton M. F., Atkinson J. B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995 Feb 17;267(5200):1034–1037. doi: 10.1126/science.7863332. [DOI] [PubMed] [Google Scholar]
  20. Mabuchi H., Itoh H., Takeda M., Kajinami K., Wakasugi T., Koizumi J., Takeda R., Asagami C. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency. Metabolism. 1989 Feb;38(2):115–119. doi: 10.1016/0026-0495(89)90249-7. [DOI] [PubMed] [Google Scholar]
  21. Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  22. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., Pitas R. E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994 May 6;264(5160):850–852. doi: 10.1126/science.8171342. [DOI] [PubMed] [Google Scholar]
  23. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992 Oct 16;71(2):343–353. doi: 10.1016/0092-8674(92)90362-g. [DOI] [PubMed] [Google Scholar]
  24. Rall S. C., Jr, Mahley R. W. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992 Jun;231(6):653–659. doi: 10.1111/j.1365-2796.1992.tb01254.x. [DOI] [PubMed] [Google Scholar]
  25. Stevenson S. C., Marshall-Neff J., Teng B., Lee C. B., Roy S., McClelland A. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol. 1995 Apr;15(4):479–484. doi: 10.1161/01.atv.15.4.479. [DOI] [PubMed] [Google Scholar]
  26. Strittmatter W. J., Roses A. D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4725–4727. doi: 10.1073/pnas.92.11.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tsukamoto K., Watanabe T., Matsushima T., Kinoshita M., Kato H., Hashimoto Y., Kurokawa K., Teramoto T. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med. 1993 Apr;121(4):598–602. [PubMed] [Google Scholar]
  28. Vilquin J. T., Guérette B., Kinoshita I., Roy B., Goulet M., Gravel C., Roy R., Tremblay J. P. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995 Nov;6(11):1391–1401. doi: 10.1089/hum.1995.6.11-1391. [DOI] [PubMed] [Google Scholar]
  29. Weisgraber K. H., Innerarity T. L., Mahley R. W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982 Mar 10;257(5):2518–2521. [PubMed] [Google Scholar]
  30. Wilson J. M. Adenoviruses as gene-delivery vehicles. N Engl J Med. 1996 May 2;334(18):1185–1187. doi: 10.1056/NEJM199605023341809. [DOI] [PubMed] [Google Scholar]
  31. Wilson P. W., Myers R. H., Larson M. G., Ordovas J. M., Wolf P. A., Schaefer E. J. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994 Dec 7;272(21):1666–1671. [PubMed] [Google Scholar]
  32. Yang Y., Ertl H. C., Wilson J. M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994 Aug;1(5):433–442. doi: 10.1016/1074-7613(94)90074-4. [DOI] [PubMed] [Google Scholar]
  33. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ye X., Robinson M. B., Batshaw M. L., Furth E. E., Smith I., Wilson J. M. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem. 1996 Feb 16;271(7):3639–3646. doi: 10.1074/jbc.271.7.3639. [DOI] [PubMed] [Google Scholar]
  35. Zhang S. H., Reddick R. L., Piedrahita J. A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992 Oct 16;258(5081):468–471. doi: 10.1126/science.1411543. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES